Earnings Call · Q4 FY2022·2023-02-28

Q4 22EPS -12.20%·Rev n/aQ3 22EPS -19.86%·Rev n/aQ2 22EPS -2.60%·Rev n/aQ1 22EPS -39.84%·Rev n/a⚠ consensus missing

REGENXBIO Inc. RGNX

Patrick Christmas — Investor Relations

Ken Mills — Chief Executive Officer

Steve Pakola — Chief Medical Officer

Vit Vasista — Chief Financial Officer

+8.5%1d on move date+8.9% vs SPY3d+9.6%5d+5.3%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RGNX calls or request research access.

More RGNX calls Browse calls Request research access